Cyrano Therapeutics reported its Phase 2 Flavor study met the primary endpoint for treating persistent smell loss and plans a pivotal Phase 3 trial in the second half of the year.
Longevity News
Cyrano Therapeutics is savoring a phase 2 victory.
Source: FierceBiotech - All • Published: 20 Feb 2026, 04:51
Continue exploring
Related longevity signals
Longevity TechnologyNRG Therapeutics shows promising lab results for new ALS drug candidateNRG Therapeutics’ preclinical report invites readers to examine lab and mechanistic data for a novel ALS drug candidate and its next-stage plans.PR NewswireCARsgen Therapeutics Announces 2026 Interim ResultsReport on a CAR T developer's 2026 interim results covering commercial progress, regulatory milestones, and clinical updates for multiple CAR T programs.Nature - BiotechnologyOral nonpeptide GLP-1 receptor agonist VCT220 for obesity treatment: a randomized, double-blind, phase II trialReports a multicenter phase II trial testing an oral nonpeptide GLP-1 receptor agonist for obesity, its dosing options, and short-term efficacy and tolerability.Nature - BiotechnologyMRNA-LNP therapeutics for obesity: weight loss with metabolic repairMRNA-LNP approaches that program tissues to produce therapeutic proteins for obesity, outlining advances in delivery strategies and therapeutic potential.